NGF Treatment for Patients With Neuropathic Corneal Pain

Status Withdrawn

Clinical Trial Summary

This prospective, single center, interventional, open-label, single arm, non-randomized trial seeks to investigate the efficacy of Oxervate® (cenergermin 0.002% eye drops) on ameliorating the signs and symptoms of neuropathic corneal pain (NCP). The study aims to enroll 28 subjects with NCP. All patients will be evaluated for clinical symptoms and signs of NCP, corneal staining and nerve regeneration (by IVCM) at Baseline (Visit 2) through the end of study (16 weeks post treatment).

Clinical Trial Description

During the screening (Visit 1 / Day -8) all procedures for inclusion will be performed. From the day of screening the participants will stop any kind of further previous ocular treatment regime, except commercially available preservative free artificial tears provided by Sponsor for 7 days and 9 days as maximum (day -8 to day -1+2) until the baseline(Visit 2) . At the end of the washout period (day -8 to day -1+2), participants meeting the entry criteria for this study will be assigned to receive the Oxervate® at 4times/daily dosing in both eyes for 4 weeks. At Week 1, participants will be queried for adverse events. If the participant reports side effects while on 4times/daily dosing, subjects will be instructed to begin a modified dosing regimen: 4 times daily for 3 days, then 1 day off dosing. At Week 4, participants will be evaluated for clinically significant changes. If resolution of NCP or improvement is observed, Oxervate® will be discontinued. If there is partial/no-improvement, participants will be instructed to begin an increased dosing regimen of 6times/daily. If at any point during the intervention period ocular pain/irritation is worsened for a prolonged period, Oxervate® intervention will be discontinued. During the 8 weeks of intervention, only the administration of Oxervate® is allowed. Nevertheless, if strictly needed, the participant can take preservative free artificial tears (provided by Sponsor). The use (n° drops/day) of preservative free artificial tears will be clearly documented in a participant's diary and in the CRF. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05700864
Study type	Interventional
Source	Tufts Medical Center
Contact
Status	Withdrawn
Phase	Phase 1
Start date	November 1, 2022
Completion date	December 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03195868` - Photobiomodulation Therapy and Nerve Density for Patients With Diabetic or Chemotherapy-associated Neuropathy	N/A
Not yet recruiting	`NCT05565469` - Correlation Between Abdominal Wall Stimulation and Neurostimulator Tip Location	N/A
Completed	`NCT02309164` - The Use of Acupuncture for Treatment of Chemotherapy-induced Peripheral Neuropathy (CIPN).	N/A
Completed	`NCT00775645` - S0715: Acetyl-L-Carnitine in Preventing Neuropathy in Women With Stage I, Stage II, or Stage IIIA Breast Cancer Undergoing Chemotherapy	Phase 3
Completed	`NCT03624426` - Detection and Prevention of Nerve Injury in Shoulder Arthroplasty Surgery	N/A
Withdrawn	`NCT03436680` - Home-Based Neurofeedback Program in Treating Participants With Chemotherapy-Induced Peripheral Neuropathy	N/A
Completed	`NCT05691738` - Effects of Modified Otago Exercises in Individuals With Diabetic Neuropathy	N/A
Completed	`NCT05095870` - Evaluation of the Peripheral Nerve Ultrasound as a Diagnostic Tool in CANVAS Neuropathies
Completed	`NCT02615678` - Acupuncture for CIPN in Breast Cancer Patients	N/A
Completed	`NCT02011282` - Electro-Neuro-Muscular Stimulation in ICU	N/A
Recruiting	`NCT01774058` - The Arterial Measurement of the Blood Flow Volume After Iloprost Stimulation	Phase 2
Completed	`NCT01135251` - Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy	Phase 2
Recruiting	`NCT06324344` - Transcutaneous Electrical Nerve Stimulation (TENS) for Chemotherapy Induced Peripheral Neuropathy (CIPN)	N/A
Recruiting	`NCT04403802` - Voxx Human Performance Technology Socks for Chemotherapy-Induced Peripheral Neuropathy	N/A
Recruiting	`NCT04579406` - Perioperative Adverse Cardiovascular Event in Type-2 Diabetic Patients
Recruiting	`NCT03881930` - Balance Rehabilitation With Modified Visual Input in Patients With Neuropathy	N/A
Completed	`NCT03909464` - Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy
Completed	`NCT01523132` - Persistent Pain After Breast Cancer Treatment (PPBCT) - Risk Factors and Pathophysiological Mechanisms	N/A
Completed	`NCT02689661` - Impact of the Metabolic Syndrome on the Incidence of Neuropathy in Obese Subjects
Terminated	`NCT00998738` - Calcium and Magnesium in Preventing Peripheral Neuropathy Caused by Ixabepilone in Patients With Breast Cancer	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.